gfh009
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Genfleet Therapeutics (Shanghai) Inc.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
135 Active assets in the Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 BeBetter Med Inc | Phase 4 | BBB |
PREDNISONE TABLETS Tarapeutics Science Inc. | Phase 4 | BBB |
Pralatrexate Peking University People's Hospital | Phase 4 | BBB |
(+)-VINCRISTINE BeBetter Med Inc | Phase 4 | BBB |
Cyclophosphamide Tarapeutics Science Inc. | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
gfh009 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →